跳到主要內容

臺灣博碩士論文加值系統

(44.211.117.197) 您好!臺灣時間:2024/05/22 01:44
字體大小: 字級放大   字級縮小   預設字形  
回查詢結果 :::

詳目顯示

我願授權國圖
: 
twitterline
研究生:黃奕堯
研究生(外文):Yi-Yao Huang
論文名稱:探討LIGHT與上皮性卵巢癌病人預後的相關性
論文名稱(外文):The Correlation of LIGHT and The Outcome of Epithelial Ovarian Carcinoma Patients
指導教授:李建南李建南引用關係
指導教授(外文):Chien-Nan Lee
口試委員:陳宇立
口試委員(外文):Yu-Li Chen
口試日期:2015-06-20
學位類別:碩士
校院名稱:國立臺灣大學
系所名稱:分子醫學研究所
學門:醫藥衛生學門
學類:醫學學類
論文種類:學術論文
論文出版年:2015
畢業學年度:103
語文別:中文
論文頁數:36
中文關鍵詞:卵巢癌預後腫瘤免疫學HVEM(TNFRSF14)LIGHT(TNFSF14)BTLA
外文關鍵詞:ovarian cancer prognosiscaner-immunologyHVEM(TNFRSF14)LIGHT(TNFSF14)BTLA
相關次數:
  • 被引用被引用:0
  • 點閱點閱:218
  • 評分評分:
  • 下載下載:0
  • 收藏至我的研究室書目清單書目收藏:0
研究目標
  測量HVEM、LIGHT及BTLA的表現量與上皮性卵巢癌病人預後的關聯性。
研究材料與方法
  使用反轉錄聚合酵素連鎖反應(Reverse-transcription polymerase chain reaction, RT-PCR)和即時定量聚合酶鏈鎖反應(real-time quantitative reverse-transcription polymerase chain reaction, RTQ RT-PCR)的方法去偵測上皮性卵巢癌病人中HVEM、LIGHT、BTLA的表現程度。我們統計病人的臨床病理結果與生物指標,包括癌症的期別(disease stage)、病理組織型態(histology)、腫瘤惡性程度(tumor grade)、是否接受理想的減積手術(optimal debulking surgery)、病人術後化學治療療效 (chemotherapeutic response)以及HVEM、LIGHT及BTLA在癌組織中的表現量。再將這些因子與病人的無癌症復發期(disease-free survival)及整體存活率(overall survival)做進一步的分析。
研究結果
在所有254個上皮性卵巢癌的病人當中,平均年齡為53.3歲。其中有61位為早期卵巢癌病人,193位為晚期卵巢癌病人。57.8%的病人其病理組織型態為漿液性(serous)卵巢癌。全部病人的組織檢體中皆有LIGHT表現,但僅有154人檢測到有表現BTLA。在預後分析中,利用多變項統計分析後發現剩餘腫瘤是否大於1 cm (HR:2.9 (1.7-4.8), p<0.001)、LIGHT表現量高(HR:1.6 (1.2-2.1), p=0.001)為整體存活期之預後預測因子。此外,剩餘腫瘤是否大於1 cm (HR: 2.1 (1.5-2.9), p<0.001)、LIGHT表現量高(HR:2.1 (1.7-2.5), p<0.001)亦為無癌症復發期之預後預測因子。
我們將LIGHT表現量高低分組後,計算無癌症復發期及整體存活期之存活曲線。發現LIGHT表現量低的分組較表現量高的分組有較佳的無癌症復發期(Ptrend<0.001)及整體存活期(Ptrend=0.03)。而LIGHT表現量高低與BTLA表現量高低呈現正相關(p<0.001)。我們的研究亦發現,LIGHT表現量高低亦與上皮性卵巢癌病患對術後化療藥物治療反應有關。對化療藥物治療效果較佳(chemo-sensitive)的患者通常有較低的LIGHT表現量(P<0.001)。
研究結論
在卵巢癌腫瘤組織上的LIGHT表現量可以做為預測上皮性卵巢癌患者預後的無癌復發期及整體存活期獨立之預後因子。因此,LIGHT表現量具有潛力用來做為預測卵巢癌預後參考。

Objective
To explore the correlation between HVEM、LIGHT and BTLA expression levels in cancerous tissue and the prognosis of patients with epithelium ovarian carcinomas.
Materials and Methods
The expression levels of HVEM、LIGHT、BTLA in epithelial ovarian carcinoma tissue were measured by reverse-transcription polymerase chain reaction, (RT-PCR) and real-time quantitative reverse-transcription polymerase chain reaction (RTQ RT-PCR). Clinico-pathologic parameters and biomarkers including disease stage, histology, tumor grade, surgical status, chemotherapeutic response and HVEM, LIGHT and BTLA expression levels in cancerous tissues were used for prognostic factors to predict the disease-free survival (DFS) and overall survival (OS) of ovarian cancer patients.
Results
The mean age of 254 ovarian cancer patients are 53.3 years old. Sixty-one out of 254 were diagnosed as early ovarian carcinomas while the remaining 193 were as advanced diseases. 57.8% of the studied population were serous ovarian carcinoma. LIGHT could be detected in all the cancerous specimens but BTLA only could be detected in 154 cases. In the multivariate analysis, sub-optimal surgery (residual tumor size > 1 cm) [hazard ratio (HR): 2.9, 95% confidence interval (CI) 1.7-2.8, p<0.001] and higher LIGHT expression levels [HR: 1.6, 95% CI 1.2-2.1, p=0.001] were independent prognostic factors of OS. In addition, sub-optimal surgery (residual tumor size > 1 cm) [HR: 2.1, 95% CI 1.5-2.9, p<0.001] and higher LIGHT expression levels [HR: 2.1, 95% CI 1.7-2.5, p<0.001] were independent prognostic factors of DFS.
According the expression levels of LIGHT in cancerous tissues, the studied could be divided into three groups. In this study, the patients with lower LIGHT expression levels had longer DFS (Ptrend<0.001) and OS (Ptrend=0.03) than those with higher LIGHT expression levels. Furthermore, the LIGHT expression levels positively correlated to the BTLA expression levels (p<0.001) in this study. The tumors in the LIGHT higher expression group were less chemo-seneitive (p<0.001).
Conclusions
The patients with higher LIGHT expression levels in ovarian cancerous tissue would have shorter DFI and OS. The LIGHT expression levels may be a potential biomarker for predicting the prognosis of ovarian cancer patients.


口試委員審定書.........................................................................................i
誌謝............................................................................................................ii
中文摘要...................................................................................................iii
英文摘要...................................................................................................v
目錄..........................................................................................................vii
第一章 序言.............................................................................................1
第二章 材料與方法.................................................................................5
第三章 實驗結果.....................................................................................9
第四章 討論............................................................................................14
第五章 結論............................................................................................18
第六章 展望與未來................................................................................19
參考文獻..................................................................................................20
附錄
表1...........................................................................................................25
表2...........................................................................................................27
表3...........................................................................................................28
表4...........................................................................................................29
圖1...........................................................................................................30
圖2...........................................................................................................31
圖3...........................................................................................................32
圖4...........................................................................................................33
圖5...........................................................................................................34
圖6...........................................................................................................35
圖7...........................................................................................................36


1.Boyle P, Maisonneuve P, Autier P. Update on cancer control in women. Int J Gynaecol Obstet 2000; 70: 263-303.
2.Gonzalez DP, Lopez AG, Pollan M, Ruiz M. Time trends in ovarian cancer mortality in Europe (1955-1993): effect of age, birth cohort and period of death. Eur J Cancer 2000; 36: 1816-24.
3.Jemal, A, Thomas, A, Murray, T, & Thun, M. Cancer statistics, 2002.CA: a cancer journal for clinicians 2000; 52(1): 23-47.
4.Ozols, RF. Management of advanced ovarian cancer consensus summary. Advanced Ovarian Cancer Consensus Faculty. Semin Oncol 2000; 27: 47-9.
5.Holschneider CH, Berek JS. Ovarian cancer:epidemiology, biology, and prognosticfactors. Semin Surg Oncol 2000; 19: 3-10.
6.Rubin SC, Randall TC, Armstrong KA. Ten-year follow-up of ovarian cancer patients after second-look laparotomy with negative findings. Obstet Gynecol 1999; 93: 21-4.
7.Jacobs I, Bast RC Jr. The CA 125 tumour-associated antigen: a review of the literature. Hum Reprod 1989; 4: 1-12.
8.Schumacher K, Haensch W, Roefzaad C, et al. Prognostic significance of activated CD8(+) T cell infiltrations within esophageal carcinomas. Cancer Res 2001; 61: 3932-6.
9.Marrogi AJ, Munshi A, Merogi AJ, et al. Study of tumor infiltrating lymphocytes and transforming growth factor-beta as prognostic factors in breast carcinoma. Int J Cancer 1997; 74: 492-501.
10.Vesalainen S, Lipponen P, Talja M, Syrjanen K. Histological grade, perineural infiltration, tumour-infiltrating lymphocytes and apoptosis as determinants of long-term prognosis in prostatic adenocarcinoma. Eur J Cancer 1994; 30A: 1797-803.
11.Halpern AC, Schuchter LM. Prognostic models in melanoma. Semin Oncol 1997; 24: Suppl 4:S2-S7.
12.Naito Y, Saito K, Shiiba K, et al. CD8+ T cells infiltrated within cancer cell nests as a prognostic factor in human colorectal cancer. Cancer Res 1998; 58: 3491-4.
13.Matthew V, Glenn D. Combining immunotherapy and targeted therapies in cancer treatment. Nature Reviews Cancer 2012;12:237-251.
14.Couzin-Frankel J. Cancer immunotherapy. Science 2013;342(6165): 1432-1433.
15.Schreiber RD, Old LJ, Smyth MJ. Cancer immunoediting: integrating immunity’s roles in cancer suppression and promotion. Science 2011; 331: 1565-70.
16.Hanahan D, Weinberg RA. Hallmarks of cancer: the next generation. Cell 2011; 144: 646-74.
17.Rosenberg SA, Restifo NP, Yang JC, Morgan RA, & Dudley ME. Adoptive cell transfer: a clinical path to effective cancer immunotherapy. Nature Reviews Cancer 2008;8(4): 299-308.
18.Zhang L, Conejo JR, Katsaros D, Gimotty PA, et al. Intratumoral T cells, recurrence, and survival in epithelial ovarian cancer. New England Journal of Medicine 2003; 348(3): 203-13.
19.Sato E, Olson SH, Ahn J, Bundy B, Nishikawa H, et al. Intraepithelial CD8+ tumor-infiltrating lymphocytes and a high CD8+/regulatory T cell ratio are associated with favorable prognosis in ovarian cancer. Proc Natl Acad Sci USA 2005; 102: 18538-43
20.Morishige T, Yoshioka Y, Inakura H, et al. LIGHT protein suppresses tumor growth by augmentation of immune response. Immunology letters, 2009; 127(1): 33-38.
21.Paulos CM, Carl HJ. Putting the brakes on BTLA in T cell–mediated cancer immunotherapy. J Clin invest 2010; 120(1): 76-86.
22.Sobin LH, Fleming ID. TNM Classification of Malignant Tumors, 5th. Cancer 1997; 80(9): 1803-04.
23.Shepherd J H. Revised FIGO staging for gynecological cancer. British Journal of Obstetrics and Gynecology 1989; 96(8): 889-892.
24.Malkasian Jr GD, Melton III LJ, O''Brien PC, Greene MH. Prognostic significance of histologic classification and grading of epithelial malignancies of the ovary. AmJ Obstet Gynecol 1984; 149: 274–84.
25.Chen YL, Cheng WF, Chang MC, Lin HW, et al. Interferon-gamma in ascites could be a predictive biomarker of outcome in ovarian carcinoma. Gynecol Oncol 2013; 131(1): 63-8.
26.Raspollini MR, Castiglione F, Rossi DD, et al. Tumor-infiltrating gamma/delta T-lymphocytes are correlated with a brief disease-free interval in advanced ovarian serous carcinoma. Ann Oncol 2005; 16: 590-6.
27.Tomšová M, Melichar B, Sedláková I, Šteiner I. Prognostic significance of CD3+ tumor-infiltrating lymphocytes in ovarian carcinoma. Gynecol Oncol 2008; 108(2): 415-20.
28.Baecher AC, Anderson DE. Regulatory cells and human cancer. Semin Cancer Biol 2006; 16: 98-105.
29.Whitbeck JC, Peng C, Lou H, Xu R, Willis SH, et al. Glycoprotein D of herpes simplex virus (HSV) binds directly to HVEM, a member of the tumor necrosis factor receptor superfamily and a mediator of HSV entry. Journal of virology 1997; 71(8): 6083-6093.
30.Sedy JR, Gavrieliet MP, Hurchla MA, et al. B and T lymphocyte attenuator regulates T cell activation through interaction with herpesvirus entry mediator. Nature immunology 2005; 6(1) : 90-98.
31.Duhen T, Pasero C, Mallet F, Barbarat B, Olive D, Costello RT, et al. LIGHT costimulates CD40 triggering and induces immunoglobulin secretion; a novel key partner in T cell‐dependent B cell terminal differentiation. European journal of immunology 2004; 34(12): 3534-3541.
32.Ware CF. Targeting lymphocyte activation through the lymphotoxin and LIGHT pathways. Immunological reviews 2008; 223(1): 186-201.
33.Bodmer JL, Pascal S, and Jürg T. The molecular architecture of the TNF superfamily. Trends in biochemical sciences 2002; 27.1: 19-26.
34.Derré L, Rivals JP, Jandus C, Pastor S, Rimoldi D, et al. BTLA mediates inhibition of human tumor-specific CD8+ T cells that can be partially reversed by vaccination. J Clin invest 2010; 120(1): 157-67.
35.Zhai Y, Guo R, Hsu TL, Yu GL, Ni J, et al. LIGHT, a novel ligand for lymphotoxin beta receptor and TR2/HVEM induces apoptosis and suppresses in vivo tumor formation via gene transfer. J Clin Invest. 1998; 102(6): 1142-51.
36.Croft M. The evolving crosstalk between co-stimulatory and co-inhibitory receptors: HVEM–BTLA. Trends in immunology 2005; 26(6): 292-294.
37.Compaan DM, Gonzalez LC, Tom I, Loyet KM, Eaton D, Hymowitz SG. Attenuating lymphocyte activity: the crystal structure of the BTLA-HVEM complex. J Biol Chem 2005; 280: 39553–61.
38.Cai G, Freeman G J. The CD160, BTLA, LIGHT/HVEM pathway: a bidirectional switch regulating T‐cell activation. Immunological reviews 2009; 229(1): 244-258.
39.Banner DW, D''Arcy A, Janes W, Gentz R, Schoenfeld HJ, Broger, et al. Crystal structure of the soluble human 55 kd TNF receptor-human TNFβ complex: implications for TNF receptor activation. Cell 1993; 73.3: 431-445.
40.Watanabe N, Gavrieli M, Sedy JR, Yang J, Fallarino F, Loftin SK, et al. BTLA is a lymphocyte inhibitory receptor with similarities to CTLA-4 and PD-1. Nature immunology 2003; 4.7: 670-679.
41.Cai G, Anumanthan A, Brown JA, Greenfield EA, Zhu B & Freeman G J. CD160 inhibits activation of human CD4+ T cells through interaction with herpesvirus entry mediator. Nature immunology 2008; 9(2): 176-185.
42.Maiza H, Leca G, Mansur IG, Schiavon V, Boumsell L, Bensussan A. A novel 80-kD cell surface structure identifies human circulating lymphocytes with natural killer activity. J Exp Med 1993; 178: 1121–26.
43.Anumanthan A, Bensussan A, Boumsell L, Christ AD et al. Cloning of BY55, a novel Ig superfamily member expressed on NK cells, CTL, and intestinal intraepithelial lymphocytes. J Immunol 1998;161:2780–2790.
44.Morel Y, de Colella JMS, Harrop J, Deen KC, Holmes SD, et al. Reciprocal expression of the TNF family receptor herpes virus entry mediator and its ligand LIGHT on activated T cells: LIGHT down-regulates its own receptor. J Immunol. 2000;165(8):4397–4404.


QRCODE
 
 
 
 
 
                                                                                                                                                                                                                                                                                                                                                                                                               
第一頁 上一頁 下一頁 最後一頁 top